Fibromyalgia and Cannabinoid Research: What the Evidence Actually Shows

Fibromyalgia is a chronic condition characterised by widespread musculoskeletal pain, fatigue and disturbed sleep. It is also one of the conditions most frequently named in consumer marketing of hemp-derived products, which is exactly why buyers in this sector need two separate answers: what the published research supports, and what European law allows a business to say. This article covers both. It is informational and is not medical advice.

The most rigorous synthesis remains the Cochrane review by Walitt and colleagues (2016). Searching for controlled trials of cannabinoids in fibromyalgia, the reviewers found only two small studies, both of the synthetic cannabinoid nabilone, with 32 and 40 participants. Their conclusion was that there is no convincing, unbiased, high-quality evidence that nabilone is of value in treating people with fibromyalgia. They rated the certainty of evidence as very low across all outcomes and noted that tolerability was poor.

A more recent systematic review (Strand and colleagues, Biomedicines, 2023) reached a similarly cautious position. It described low-quality evidence for short-term pain reduction and listed substantial limitations: heterogeneous preparations, doses and routes of administration that could not meaningfully be compared, notable attrition, and follow-up periods too short to support conclusions about sustained effect.

The honest summary is that this research is early and inconsistent. Scientific interest is real; proof is not established. A supplier or brand that presents cannabinoids as an effective treatment for fibromyalgia is going well beyond what the literature currently supports.

EU law does not permit a food or supplement to be presented as preventing, treating or curing a disease. Health claims are governed by Regulation (EC) No 1924/2006, under which claims must be authorised before use. The European Union Drugs Agency states the position plainly: claims that a product prevents or treats disease are not permitted, and making them can bring the product within medicines legislation, which requires a licence.

For cannabidiol there is a second constraint. CBD is treated as a novel food in the EU, requiring authorisation before it is placed on the market as a food or supplement. In February 2026 EFSA published a provisional safe level for CBD of 0.0275 mg per kg of body weight per day, roughly 2 mg for a 70 kg adult, for supplements meeting defined purity criteria. EFSA also stated that safety cannot be established for people under 25, for pregnant and breastfeeding women, or for people taking medication, and that data gaps remain.

For a B2B buyer, that translates into a short set of working rules:

• Describe the material, not an outcome. Cannabinoid and terpene profile, purity, extraction method, batch testing, origin and format are all fair game. What the material will do for the person who eventually uses it is not.
• Do not name a disease anywhere: product copy, page title, meta description, image filename, or paid search keyword.
• Treat testimonials as claims. A customer quotation saying a product relieved a condition is a claim you are making.
• Check each destination market. National rules on CBD in food, cosmetics and smokable form vary across the EU, and several are stricter than the EU baseline.
• Keep the Certificate of Analysis with the batch. Compliance questions are answered with documents, not with adjectives.

Consumer demand connected to chronic pain is genuine and is not going away. For a compliant brand the opportunity lies in quality and transparency rather than in claims: consistent cannabinoid profiles, complete third-party testing and honest labelling. Businesses serving this segment typically build on isolates, broad-spectrum and full-spectrum materials, oils, extracts and cosmetic bases, supplied as ingredients and described as ingredients.

What the field lacks is large, well-controlled trials using standardised preparations and adequate follow-up. Both reviews cited above make that point explicitly. Until such trials report, the defensible position for a supplier is to follow the evidence rather than anticipate it, and to help customers build products that will still be lawful if the evidence never arrives.

This article is published for information only. It is not medical advice and is not a substitute for consultation with a qualified healthcare professional. Hemporium supplies raw materials and finished goods to businesses. Our products are not medicines, are not intended to diagnose, treat, cure or prevent any disease, and we do not recommend their use for any medical purpose. Buyers remain responsible for the compliance of their own finished products and claims in their destination markets.